[Morel-Lavallee syndrome of the lower leg].

É. Archier,J.-C. Grillo,S. Fourcade,C. Gaudy,Jean-Jacques Grob,Michel Richard

DOI: https://doi.org/10.1016/j.annder.2011.12.032

IF: 0.934

2012-03-01

Annales de Dermatologie et de Vénéréologie

Abstract:

What problem does this paper attempt to address?

The progress of virus-targeted new therapy against Epstein-Barr virus-associated malignancies

樊世杰,熊小龙,郑毅雄,黄凌娜,昂健

DOI: https://doi.org/10.3781/j.issn.1000-7431.2014.02.014

2014-01-01

Tumori

Abstract:The Epstein-Barr virus (EBV) has been demonstrated to be associated with several human tumors, including nasopharyngeal carcinoma (NPC), Burkitt’s lymphoma (BL), post-transplant lymphoproliferative disease (PTLD), Hodgkin’s lymphoma (HL), non-Hodgkin’s lymphomas (NHL) and gastric cancer (GC). In most EBV-associated malignancies, the tumor cells contain the viral genome. This provides a unique opportunity to develop therapeutic strategies utilizing the viral genome of EBV as a potential drug target. This review focuses on different therapeutic strategies against EBV-associated malignancies, further discusses the possible therapeutic approach using drug-induced virus activation and its certain pathways. DOI:10.3781/j.issn.1000-7431.2014.02.014
Epstein-Barr Virus Variation in People Living with Human Immunodeficiency Virus in Southeastern China.

Zhikai Wan,Ying Chen,Jiangjin Hui,Yongzheng Guo,Xiaorong Peng,Mengyan Wang,Caiqin Hu,Yirui Xie,Junwei Su,Ying Huang,Xiaoke Xu,Yan Xu,Biao Zhu

DOI: https://doi.org/10.1186/s12985-023-02078-z

IF: 5.916

2023-01-01

Virology Journal

Abstract:Background Patients infected with HIV are at high risk of developing Epstein-Barr Virus (EBV)-related diseases. The genotype and viral biological behavior of EBV infection in patients with human immunodeficiency virus-1 (HIV) in China remain unclear. This study analyzed the characteristics of EBV in patients infected with HIV in southeastern China. Methods A total of 162 HIV-infected patients and 52 patients without HIV were enrolled in this study. EBV viral load in blood was determined by fluorescence quantitative PCR. EBV typing was performed using saliva according to polymorphisms in the EBNA3C region. EBV LMP-1 carboxy terminus (C-ter) was sequenced, and compared with the epidemic strains in the world. Results Among HIV infected patients, the EBV strain variant was mainly EBV-1, while EBV-2 had a higher viral load than EBV-1 (P = 0.001) and EBV-1/2 (P = 0.002). HIV infected patients had higher active virus replication. The EBV LMP-1 variants were mainly the China1 variant. HIV-infected patients had different nucleic acid positions of 30-bp deletion (del30) and had a higher incidence of high 33-bp tandem repeats (rep33) copies than non-HIV-infected patients. There was a difference in the mutations of EBV LMP-1 C-ter del30 and ins15 between HIV infected patients and the control group (P < 0.001). Conclusion In southeastern China, EBV in HIV-infected patients had higher active virus replication; EBV infection was mainly EBV-1, and EBV-2 infection has higher EBV virus load; hotspot mutations of LMP-1 C-ter were different between HIV-infected patients and non-HIV-infected patients. Trial registration : This study was approved by the ethics committee of the First Affiliated Hospital of Zhejiang University School of Medicine (Approval No. 2018764), and registered in Chinese Clinical Trial Registry on 3 June 2019 (ChiCTR, ChiCTR1900023600, http://www.chictr.org.cn/usercenter.aspx ).
Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases

Xinle Cui,Clifford M. Snapper

DOI: https://doi.org/10.3389/fimmu.2021.734471

IF: 7.3

2021-10-08

Frontiers in Immunology

Abstract:Epstein-Barr virus (EBV) is the first human tumor virus discovered and is strongly implicated in the etiology of multiple lymphoid and epithelial cancers. Each year EBV associated cancers account for over 200,000 new cases of cancer and cause 150,000 deaths world-wide. EBV is also the primary cause of infectious mononucleosis, and up to 70% of adolescents and young adults in developed countries suffer from infectious mononucleosis. In addition, EBV has been shown to play a critical role in the pathogenesis of multiple sclerosis. An EBV prophylactic vaccine that induces neutralizing antibodies holds great promise for prevention of EBV associated diseases. EBV envelope proteins including gH/gL, gB and gp350 play key roles in EBV entry and infection of target cells, and neutralizing antibodies elicited by each of these proteins have shown to prevent EBV infection of target cells and markedly decrease EBV titers in the peripheral blood of humanized mice challenged with lethal dose EBV. Recent studies demonstrated that immunization with the combination of gH/gL, gB and/or gp350 induced markedly increased synergistic EBV neutralizing activity compared to immunization with individual proteins. As previous clinical trials focused on gp350 alone were partially successful, the inclusion of gH/gL and gB in a vaccine formulation with gp350 represents a promising approach of EBV prophylactic vaccine development. Therapeutic EBV vaccines have also been tested clinically with encouraging results. Immunization with various vaccine platforms expressing the EBV latent proteins EBNA1, LMP1, and/or LMP2 promoted specific CD4+ and CD8+ cytotoxic responses with anti-tumor activity. The addition of EBV envelope proteins gH/gL, gB and gp350 has the potential to increase the efficacy of a therapeutic EBV vaccine. The immune system plays a critical role in the control of tumors, and immune cell therapy has emerged as a promising treatment of cancers. Adoptive T-cell therapy has been successfully used in the prevention and treatment of post-transplant lymphoproliferative disorder. Chimeric antigen receptor T cell therapy and T cell receptor engineered T cell therapy targeting EBV latent proteins LMP1, LMP2 and/or EBNA1 have been in development, with the goal to increase the specificity and efficacy of treatment of EBV associated cancers.

immunology
Clinical analysis of Epstein-Barr virus-associated lymphoproliferative disease in children

何敏菲,黄彬晓,朱建芳,梁黎,王春林,孔元梅

DOI: https://doi.org/10.3760/cma.j.issn.1673-4408.2021.02.015

2021-01-01

International Journal of Pediatrics

Abstract:Objective:To investigate the clinical features of Epstein-Barr virus associated lymphoproliferative disease in children and to improve the understanding of this disease.Methods:This study included the children with Epstein-Barr virus associated lymphoproliferative disease admitted to the First Affiliated Hospital of College of Medicine of Zhejiang University from January 2014 to December 2018.Data of these children were collected, including age, clinical manifestations, laboratory results, treatment and outcome.The clinical features and therapeutic effects were analyzed.Results:A total of 114 cases(mean age 6 years, 0~17 years)were enrolled in this study, including 53 males and 61 females.There were 107 cases(93.86%) in the mild group (38 cases of EBV infection and 69 cases of infectious mononucleosis) and 7 cases in the severe group (6.14%). Six cases of the severe group were T cell or NK cell proliferation.Compared with the mild group, the load of EBV-DNA was higher in the severe group, but there was no significant difference( χ2=0.957, P>0.05). The IgM in severe group was significantly lower( Z=-2.041, P<0.05). But the differences in the level of immune function including IgA, IgG, CD4 + cell and CD8 + cell between the severe group and the mild group were not significant.The cases in the mild group had improved after antiviral treatments.Among the severe group, 3 cases survived after treatment, another 1 case was diagnosed as hydroa vacciniforme-like EBV-related proliferative disease (HV-like LPD). After antiviral treatment, the effect was not good, then after high-dose IVIG treatment and Bortezomib combined with methylprednisolone treatment, the EBV-DNA load decreased and the condition improved.While 1 case lost to follow-up, there were 2 cases with EBV-associated hemophagocytic syndrome and 1 case with EBV-associated lymphoma died after chemotherapy or transplantation. Conclusion:EBV-associated lymphoproliferative disease may manifest as a condition similar to infectious mononucleosis.High IgE, low IgM or high DNA load may indicate poor prognosis.Immune function after EBV infection may have different effects on prognosis.When the infected lymphocyte types are NK or T cells, it may indicate poor prognosis.The efficacy of transplantation and chemotherapy in severe cases is still uncertain.
A survey for the presence of the amphibian chytrid fungus(Batrachochytrium dendrobatidis) in Tasmania.

D. Obendorf,A. Dalton

DOI: https://doi.org/10.26749/RSTPP.140.25

Abstract:A survey confirmed rhe presence of the amphibian chytrid fungus, Batrachochytrium dendrobatidis in a number of frog habitats dose to major cities and towns across Tasmania.The detection of chytrid infection in some remote wetlands at high altitude locations on the Tasmanian Central Plateau is of particular concern. The likely presence of chytrid infections was assessed by examining tadpoles for signs of depigmentation, thinning and asymmetry in their keratinized jaw sheaths using a hand lens. Assessing the jaw shearhs of up to 60 tadpoles combined with rhe application of rhe Taqman chytrid PCR test was a useful means of detecting the presence of chytridiomycosis at each frog habitat
Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment

Sin-Yeang Teow,Hooi-Yeen Yap,Suat-Cheng Peh

DOI: https://doi.org/10.1155/2017/7349268

2017-01-01

Journal of Pathogens

Abstract:Epstein-Barr virus (EBV) is a pathogen that infects more than 90% of global human population. EBV primarily targets B-lymphocytes and epithelial cells while some of them infect monocyte/macrophage, T-lymphocytes, and dendritic cells (DCs). EBV infection does not cause death by itself but the infection has been persistently associated with certain type of cancers such as nasopharyngeal carcinoma (NPC), Burkitt’s lymphoma (BL), and Hodgkin’s lymphoma (HL). Recent findings have shown promise on targeting EBV proteins for cancer therapy by immunotherapeutic approach. Some studies have also shown the success of adopting EBV-based therapeutic vaccines for the prevention of EBV-associated cancer particularly on NPC. In-depth investigations are in progress to refine the current therapeutic and vaccination strategies. In present review, we discuss the highly potential EBV targets for NPC immunotherapy and therapeutic vaccine development as well as addressing the underlying challenges in the process of bringing the therapy and vaccination from the bench to bedside.
Advancing therapeutic strategies for Epstein-Barr virus-associated malignancies through lytic reactivation

Haiqi Tan,Yibing Gong,Yi Liu,Jingyi Long,Qingshuang Luo,Oluwasijibomi Damola Faleti,Xiaoming Lyu

DOI: https://doi.org/10.1016/j.biopha.2023.114916

Abstract:Epstein-Barr virus (EBV) is a widespread human herpes virus associated with lymphomas and epithelial cell cancers. It establishes two separate infection phases, latent and lytic, in the host. Upon infection of a new host cell, the virus activates several pathways, to induce the expression of lytic EBV antigens and the production of infectious virus particles. Although the carcinogenic role of latent EBV infection has been established, recent research suggests that lytic reactivation also plays a significant role in carcinogenesis. In this review, we summarize the mechanism of EBV reactivation and recent findings about the role of viral lytic antigens in tumor formation. In addition, we discuss the treatment of EBV-associated tumors with lytic activators and the targets that may be therapeutically effective in the future.
New insights into Epstein-Barr virus-associated tumors: Exosomes

Wei Chen,Yao Xie,Tingting Wang,Lin Wang

DOI: https://doi.org/10.3892/or.2021.8224

2022-01-01

Oncology Reports

Abstract:Epstein-Barr virus (EBV) is endemic worldwide and is associated with a number of human tumors. EBV-associated tumors have unique mechanisms of tumorigenesis. EBV encodes multiple oncogenic molecules that can be loaded into exosomes released by EBV+ tumor cells to mediate intercellular communication. Moreover, different EBV+ tumor cells secrete exosomes that act on various target cells with various biological functions. In addition to oncogenicity, EBV+ exosomes have potential immunosuppressive effects. Investigating EBV+ exosomes could identify the role of EBV in tumorigenesis and progression. The present review summarized advances in studies focusing on exosomes and the functions of EBV+ exosomes derived from different EBV-associated tumors. EBV+ exosomes are expected to become a new biomarker for disease diagnosis and prognosis. Therefore, exosome-targeted therapy displays potential.
Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study

Ya Cao,Longlong Xie,Feng Shi,Min Tang,Yueshuo Li,Jianmin Hu,Lin Zhao,Luqing Zhao,Xinfang Yu,Xiangjian Luo,Weihua Liao,Ann M. Bode

DOI: https://doi.org/10.1038/s41392-020-00376-4

IF: 39.3

2021-01-12

Signal Transduction and Targeted Therapy

Abstract:Abstract Epstein–Barr virus-associated diseases are important global health concerns. As a group I carcinogen, EBV accounts for 1.5% of human malignances, including both epithelial- and lymphatic-originated tumors. Moreover, EBV plays an etiological and pathogenic role in a number of non-neoplastic diseases, and is even involved in multiple autoimmune diseases (SADs). In this review, we summarize and discuss some recent exciting discoveries in EBV research area, which including DNA methylation alterations, metabolic reprogramming, the changes of mitochondria and ubiquitin-proteasome system (UPS), oxidative stress and EBV lytic reactivation, variations in non-coding RNA (ncRNA), radiochemotherapy and immunotherapy. Understanding and learning from this advancement will further confirm the far-reaching and future value of therapeutic strategies in EBV-associated diseases.

biochemistry & molecular biology,cell biology
Treatment Advances in EBV Related Lymphoproliferative Diseases

Kebing Lv,Ting Yin,Min Yu,Zhiwei Chen,Yulan Zhou,Fei Li

DOI: https://doi.org/10.3389/fonc.2022.838817

IF: 4.7

2022-04-19

Frontiers in Oncology

Abstract:Epstein Barr virus (EBV) can affect 90% of the human population. It can invade B lymphocytes, T lymphocytes and natural killer cells of the host and remain in the host for life. The long latency and reactivation of EBV can cause malignant transformation, leading to various lymphoproliferative diseases (LPDs), including EBV-related B-cell lymphoproliferative diseases (EBV-B-LPDs) (for example, Burkitt lymphoma (BL), classic Hodgkin’s lymphoma (cHL), and posttransplantation and HIV-related lymphoproliferative diseases) and EBV-related T-cell lymphoproliferative diseases (EBV-T/NK-LPDs) (for example, extranodal nasal type natural killer/T-cell lymphoma (ENKTCL), aggressive NK cell leukaemia (ANKL), and peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). EBV-LPDs are heterogeneous with different clinical features and prognoses. The treatment of EBV-LPDs is usually similar to that of EBV-negative lymphoma with the same histology and can include chemotherapy, radiotherapy, and hematopoietic stem cell transplant (HSCT). However, problems such as serious toxicity and drug resistance worsen the survival prognosis of patients. EBV expresses a variety of viral and lytic proteins that regulate cell cycle and death processes and promote the survival of tumour cells. Based on these characteristics, a series of treatment strategies for EBV in related malignant tumours have been developed, such as monoclonal antibodies, immune checkpoint inhibitors, cytotoxic T lymphocytes (CTLs) and epigenetic therapy. These new individualized therapies can produce highly specific killing effects on tumour cells, and nontumour cells can be protected from toxicity. This paper will focus on the latest progress in the treatment of EBV-LPDs based on pathological mechanisms.

oncology
ON THE GAP IN HORIZONTAL BRANCHES AT B - V ABOUT ZERO

V. Caloi

1999-03-01

Abstract:It is proposed that the gap observed in the horizontal branch sequence of many globular clusters at B V about zero is due to a surface phenomenon. Stars on the hotter side of the gap - Te & 10000 K - have an atmospheric chemical composition altered as in peculiar A and B stars. The appearance of a convective regime in the surface layers at the temperature and gravity of the gap cancel the peculiarities: it is proposed that the ensuing changes in surface physical conditions give origin to the observed gap.
Study on the performance of cooling composite materials for liquid-immersed concentrating photovoltaic systems

Boyang Zhang,Yiping Wang,Qunwu Huang,Jiahe Feng,Yong Cui,Yunhui Zhang

DOI: https://doi.org/10.1016/J.SOLENER.2015.05.012

2015-09-01

Abstract:
Naming and Identity in Epistemic Logic Part II: A First-Order Logic for Naming

Adam J. Grove

DOI: https://doi.org/10.1016/0004-3702(95)98593-D

IF: 14.4

1995-04-01

Artificial Intelligence

Abstract:
Epstein–Barr Virus, the Immune System, and Associated Diseases

Mei-Ru Chen

DOI: https://doi.org/10.3389/fmicb.2011.00005

IF: 5.2

2011-01-01

Frontiers in Microbiology

Abstract:Host immune system is designed (or evolved) to fight against different pathogens. Many viruses infect the immune cells for the propagation of new progenies, thus the infection may modulate the host immune homeostasis. It has been more than 45 years since the discovery of Epstein-Barr virus (EBV) from a Burkitt's lymphoma derived cell line. The ability of EBV to transform primary B cells in vitro leads to the suggestion for its oncogenic potential. However, except the clear understanding of the role of EBV in post-transplantation lymphoproliferative disease, it remains ambiguous why such a ubiquitous virus causes malignant diseases only in a very small subset of individuals. Possible explanation is that EBV may cooperate with other environmental and host genetic factors and lead to the development of EBV associated neoplastic diseases. In addition to infecting B cells, recent studies revealed that EBV may impact host immune system more broadly than previously thought, for example the development of regulatory NKT subsets. Instead of an intensive review, this article aims to provide a linkage to recent advances on the interplay between EBV and host immune system and to inspire further studies on EBV related diseases, especially autoimmune diseases.

microbiology
Epstein-Barr Viruses: Their Immune Evasion Strategies and Implications for Autoimmune Diseases

Yuehong Zhao,Qi Zhang,Botian Zhang,Yihao Dai,Yifei Gao,Chenzhong Li,Yijing Yu,Conglei Li

DOI: https://doi.org/10.3390/ijms25158160

2024-07-26

Abstract:Epstein-Barr virus (EBV), a member of the γ-herpesvirus family, is one of the most prevalent and persistent human viruses, infecting up to 90% of the adult population globally. EBV's life cycle includes primary infection, latency, and lytic reactivation, with the virus primarily infecting B cells and epithelial cells. This virus has evolved sophisticated strategies to evade both innate and adaptive immune responses, thereby maintaining a lifelong presence within the host. This persistence is facilitated by the expression of latent genes such as EBV nuclear antigens (EBNAs) and latent membrane proteins (LMPs), which play crucial roles in viral latency and oncogenesis. In addition to their well-known roles in several types of cancer, including nasopharyngeal carcinoma and B-cell lymphomas, recent studies have identified the pathogenic roles of EBV in autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. This review highlights the intricate interactions between EBV and the host immune system, underscoring the need for further research to develop effective therapeutic and preventive strategies against EBV-associated diseases.
Epstein-Barr virus infection: the micro and macro worlds

Wei Huang,Lang Bai,Hong Tang

DOI: https://doi.org/10.1186/s12985-023-02187-9

IF: 5.916

2023-10-04

Virology Journal

Abstract:Epstein‒Barr virus (EBV) is a DNA virus that belongs to the human B lymphotropic herpesvirus family and is highly prevalent in the human population. Once infected, a host can experience latent infection because EBV evades the immune system, leading to hosts harboring the virus for their lifetime. EBV is associated with many diseases and causes significant challenges to human health. This review first offers a description of the natural history of EBV infection, clarifies the interaction between EBV and the immune system, and finally focuses on several major types of diseases caused by EBV infection.

virology
Epstein-Barr Virus and Neurological Diseases

Nan Zhang,Yuxin Zuo,Liping Jiang,Yu Peng,Xu Huang,Lielian Zuo

DOI: https://doi.org/10.3389/fmolb.2021.816098

IF: 6.113

2022-01-10

Frontiers in Molecular Biosciences

Abstract:Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a double-stranded DNA virus that is ubiquitous in 90–95% of the population as a gamma herpesvirus. It exists in two main states, latent infection and lytic replication, each encoding viral proteins with different functions. Human B-lymphocytes and epithelial cells are EBV-susceptible host cells. EBV latently infects B cells and nasopharyngeal epithelial cells throughout life in most immunologically active individuals. EBV-infected cells, free viruses, their gene products, and abnormally elevated EBV titers are observed in the cerebrospinal fluid. Studies have shown that EBV can infect neurons directly or indirectly via infected B-lymphocytes, induce neuroinflammation and demyelination, promote the proliferation, degeneration, and necrosis of glial cells, promote proliferative disorders of B- and T-lymphocytes, and contribute to the occurrence and development of nervous system diseases, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, acute cerebellar ataxia, meningitis, acute disseminated encephalomyelitis, and brain tumors. However, the specific underlying molecular mechanisms are unclear. In this paper, we review the mechanisms underlying the role of EBV in the development of central nervous system diseases, which could bebeneficial in providing new research ideas and potential clinical therapeutic targets for neurological diseases.

biochemistry & molecular biology
Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease

Mark A. Vickers,Gwen M. Wilkie,Nicolas Robinson,Nadja Rivera,Tanzina Haque,Dorothy H. Crawford,Jacqueline Barry,Neil Fraser,David M. Turner,Victoria Robertson,Phil Dyer,Peter Flanagan,Helen R. Newlands,John Campbell,Marc L. Turner

DOI: https://doi.org/10.1111/bjh.13051

2014-07-26

British Journal of Haematology

Abstract:Epstein-Barr virus (EBV) is associated with several malignancies, including post-transplant lymphoproliferative disorder (PTLD). Conventional treatments for PTLD are often successful, but risk organ rejection and cause significant side effects. EBV-specific cytotoxic T lymphocytes (CTLs) generated in vitro from peripheral blood lymphocytes provide an alternative treatment modality with few side effects, but autologous CTLs are difficult to use in clinical practice. Here we report the establishment and operation of a bank of EBV-specific CTLs derived from 25 blood donors with human leucocyte antigen (HLA) types found at high frequency in European populations. Since licensure, there have been enquiries about 37 patients, who shared a median of three class I and two class II HLA types with these donors. Cells have been infused into ten patients with lymphoproliferative disease, eight of whom achieved complete remission. Neither patient with refractory disease was matched for HLA class II. Both cases of EBV-associated non-haematopoietic sarcoma receiving cells failed to achieve complete remission. Thirteen patients died before any cells could be issued, emphasizing that the bank should be contacted before patients become pre-terminal. Thus, this third party donor-derived EBV-specific CTL cell bank can supply most patients with appropriately matched cells and most recipients have good outcomes.

hematology
Anti‐EBV antibodies: Roles in diagnosis, pathogenesis, and antiviral therapy

Chu Xie,Lan‐Yi Zhong,Guo‐Long Bu,Ge‐Xin Zhao,Bo‐Yu Yuan,Yuan‐Tao Liu,Cong Sun,Mu‐Sheng Zeng

DOI: https://doi.org/10.1002/jmv.28793

IF: 20.693

2023-05-22

Journal of Medical Virology

Abstract:Epstein‐Barr virus (EBV) infection is prevalent in global population and associated with multiple malignancies and autoimmune diseases. During the infection, EBV‐harbored or infected cell‐expressing antigen could elicit a variety of antibodies with significant role in viral host response and pathogenesis. These antibodies have been extensively evaluated and found to be valuable in predicting disease diagnosis and prognosis, exploring disease mechanisms, and developing antiviral agents. In this review, we discuss the versatile roles of EBV antibodies as important biomarkers for EBV‐related diseases, potential driving factors of autoimmunity, and promising therapeutic agents for viral infection and pathogenesis.

virology
Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction

Jing Cai,Bodou Zhang,Yuqi Li,Wanfang Zhu,Toshihiro Akihisa,Wei Li,Takashi Kikuchi,Wenyuan Liu,Feng Feng,Jie Zhang

DOI: https://doi.org/10.3390/vaccines9111290

2021-11-07

Vaccines

Abstract:The Epstein-Barr virus (EBV) infects more than 95% of adults worldwide and is associated with various malignant tumors and immune diseases, imparting a huge disease burden on the human population. Available EBV vaccines are imminent. Prophylactic vaccines can effectively prevent the spread of infection, whereas therapeutic vaccines mainly stimulate cell-mediated immunity and kill infected cells, thus curbing the development of malignant tumors. Nevertheless, there are still no approved EBV vaccines after decades of effort. The complexity of the EBV life cycle, the lack of appropriate animal models, and the limited reports on adjuvant selection and immune responses are gravely impeding progress in EBV vaccines. The soluble gp350 vaccine could reduce the incidence of infectious mononucleosis (IM), which seemed to offer hope, but could not prevent EBV infection. Continuous research and vaccine trials provide deep insights into the structural biology of viruses, the designs for immunogenicity, and the evolving vaccine platforms. Moreover, the new vaccine candidates are expected to achieve further success via combined immunization to elicit both a dual protection of B cells and epithelial cells, and sustainable immunization against infected cells at several phases of infection.

immunology,medicine, research & experimental

[Morel-Lavallee syndrome of the lower leg].

The progress of virus-targeted new therapy against Epstein-Barr virus-associated malignancies

Epstein-Barr Virus Variation in People Living with Human Immunodeficiency Virus in Southeastern China.

Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases

Clinical analysis of Epstein-Barr virus-associated lymphoproliferative disease in children

A survey for the presence of the amphibian chytrid fungus(Batrachochytrium dendrobatidis) in Tasmania.

Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment

Advancing therapeutic strategies for Epstein-Barr virus-associated malignancies through lytic reactivation

New insights into Epstein-Barr virus-associated tumors: Exosomes

Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study

Treatment Advances in EBV Related Lymphoproliferative Diseases

ON THE GAP IN HORIZONTAL BRANCHES AT B - V ABOUT ZERO

Study on the performance of cooling composite materials for liquid-immersed concentrating photovoltaic systems

Naming and Identity in Epistemic Logic Part II: A First-Order Logic for Naming

Epstein–Barr Virus, the Immune System, and Associated Diseases

Epstein-Barr Viruses: Their Immune Evasion Strategies and Implications for Autoimmune Diseases

Epstein-Barr virus infection: the micro and macro worlds

Epstein-Barr Virus and Neurological Diseases

Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease

Anti‐EBV antibodies: Roles in diagnosis, pathogenesis, and antiviral therapy

Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction